{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":true},"limitationsAndCaveats":{"description":"Study was terminated early by sponsor for strategic reasons. No participants were enrolled in Group 2 Arm 4: modakafusp alfa + bortezomib \\& Group 3 arms. Data for endpoints related to PFS, OS, DOR, TTP, TTNT, EFS, TTR, \\& MRD were not collected as planned \\& hence not reported."},"pointOfContact":{"email":"USMedInfo@tevapharm.com","organization":"Teva U.S. Medical Information","phone":"1-888-483-8279","title":"Study Director"}}